Materials of Construction Based on Recovery Data for Cleaning Validation - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Materials of Construction Based on Recovery Data for Cleaning Validation
The material of construction is a factor in the recovery of residue in cleaning validation. An analysis of existing recovery data showed that recovery factors for drug products on various materials of construction may be categorized into several groupings.

Pharmaceutical Technology

The two primary factors for statistical analysis were the material of construction and the test substance. The data were analyzed to determine if there were any trends or relationships that might be leveraged to reduce testing without compromising quality. The statistical methods used included analysis of variance to compare recovery factors across substances and materials. Variance components analysis estimated variance across sites and repeated tests. Least squares means estimated average recovery factors adjusted for different materials and substances and confidence intervals around those averages. Exploratory data analysis identified the primary causes of differences in recovery factors.

Results and discussion

Assumptions in recovery-data analysis. Although standardized methods for recovery exist throughout the company, each site that conducted recovery studies implemented these procedures with different equipment, personnel, and slight modifications to the methods and swab technique. For the purposes of this analysis, these differences were all combined into a site-to-site variance component. Specific causes of variation among sites were not explored.

Limitations. This data analysis was performed with available data from routine recovery studies at each site. There was no attempt to collect data in a structure, so the data were not balanced across materials, substances, or sites. For example, a particular product may have been studied on only one material at one site. This approach made it difficult to separate recovery differences based on materials from recovery differences attributed to substances or sites. Analysis of variance on unbalanced data is analogous to building a table with legs of unequal height. Although differences may be detected between substances or materials, they are more difficult to support if the data structure is not well balanced across test conditions.

Analysis of data from such undesigned data sets can identify differences between substances and materials, but it does not provide strong support for cause-and-effect relationships. Follow-up designed experiments will test the hypotheses generated from this initial data exploration.

Table I: Detergents and products tested.
Recovery range. The data set used for this analysis, shown in Table I, consisted of 1262 RF values obtained for 48 different substances tested on 29 different materials. The mean RF was 80 and ranged from 3 to 154. Although the majority of the substances tested were products (APIs and formulated drug substances), detergents were also tested. There were 1072 RF values available for 42 products and 190 RF values available for 6 different detergents.

Figure 1: Product recoveries by material. (FIGURE 1: MERCK & CO. INC.)
The average RF was 13 units higher for detergents than for products. This result agreed with the concept that detergents are typically formulated to be easily removed from surfaces. The standard deviations for the two groups were similar: 22 units for detergents and 19 for products. The RF ranged from 30 to 154 for detergents and from 3 to 107 for products, shown in Figure 1, which each color represents a different material group.

The recovery range for detergents was higher than expected. All of the high results were assayed using total organic carbon (TOC) analyzers, and the product data were generated using high-performance liquid chromatography. Several detergents had a low carbon load, and at low assay levels, TOC can have high recovery data accompanied with high assay variability (5). Historically, detergent-residue assays have been far enough below the ARL that the high recoveries and increased variability were not considered factors requiring additional work.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here